GNT Biotech & Medicals

Privately held: no public share price · Taiwan

Assets

(1 total)
1Total Assets
0Approved
1Phase 3 / Filed
0Phase 1–2 / Early
5Diseases
Quick filter:
Showing 1 of 1 assets
Target & Modality
Phase 3
HDACSmall molecule
Non-Small Cell Lung CancerBreast CancerDiffuse Large B-Cell LymphomaColorectal CancerNon-Hodgkin Lymphoma
HR+/HER2- Metastatic Breast Cancer, Peripheral T-Cell Lymphoma

Upcoming events

(2 total)

Estimated primary-completion dates from ClinicalTrials.gov and expected earnings reports. These are registry estimates, never confirmed readout dates; they can move as trials progress.

Add these trial readouts to your calendar: Apple or Outlook · Google Calendar · .ics link. The calendar updates when a registry date moves.

2028 (1)
May 2028 (1)
ChidamidePhase 3Colorectal Cancer
Est. primary completion 2028-05-31 · NCT06497985 · CT.gov ↗
What to watch
2032 (1)
December 2032 (1)
ChidamidePhase 3Lymphoma, T-Cell, Peripheral
Est. primary completion 2032-12 · NCT06947967 · CT.gov ↗
What to watch

See the full readout calendar ↗

Regulatory and conference events

(1)

Filings, regulator decisions, scientific presentations, topline results and licensing deals, each from a dated source. When a source gives only the month, the month is shown.

Recent

14 July 2026Topline resultHBI-8000 (chidamide)Phase 3 HBI-8000-303 (NCT04674683) of HBI-8000 plus nivolumab in advanced melanoma met its primary endpoint
HUYABIO International, LLC. · Source ↗

Financial reports

No financial reports recorded.